Scan to Download ios&Android APP

Trade Merrimack Pharmaceuticals, Inc. - MACK CFD

4.25
0.71%
  • Summary
  • Historical Data
  • Events
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 5, 2022 4.21 0.08 1.94% 4.13 4.25 4.13
Aug 4, 2022 4.25 0.21 5.20% 4.04 4.30 4.04
Aug 3, 2022 4.27 0.29 7.29% 3.98 4.30 3.74
Aug 2, 2022 4.96 0.06 1.22% 4.90 5.04 4.78
Aug 1, 2022 4.96 -0.12 -2.36% 5.08 5.08 4.93
Jul 29, 2022 5.01 0.04 0.80% 4.97 5.40 4.96
Jul 28, 2022 5.20 0.12 2.36% 5.08 5.38 4.88
Jul 27, 2022 5.05 0.06 1.20% 4.99 5.18 4.99
Jul 26, 2022 5.07 -0.24 -4.52% 5.31 5.31 5.06
Jul 25, 2022 5.15 0.16 3.21% 4.99 5.18 4.99
Jul 22, 2022 5.04 -0.66 -11.58% 5.70 5.72 4.90
Jul 21, 2022 5.70 0.00 0.00% 5.70 5.73 5.68
Jul 20, 2022 5.65 0.01 0.18% 5.64 5.71 5.64
Jul 19, 2022 5.63 -0.10 -1.75% 5.73 5.74 5.54
Jul 18, 2022 5.73 0.00 0.00% 5.73 5.92 5.72
Jul 15, 2022 5.72 0.13 2.33% 5.59 5.76 5.57
Jul 14, 2022 5.67 -0.26 -4.38% 5.93 5.98 5.56
Jul 13, 2022 5.85 0.26 4.65% 5.59 5.98 5.49
Jul 12, 2022 5.82 0.00 0.00% 5.82 5.87 5.67
Jul 11, 2022 5.88 0.01 0.17% 5.87 5.89 5.65

Merrimack Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, August 8, 2022
No events scheduled
View all events

Still looking for a broker you can trust?

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Merrimack Pharmaceuticals, Inc. Company profile

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $2M. Higher net loss reflects Gain on sale of assets decrease of 93% to $144K (income), Interest income decrease of 61% to $19K (income), Other income (expense), net decrease from $18K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.15.

Equity composition

Common Stock $0.01 Par, 02/12, 200M auth., 94,756,679 issd. Insiders own 9.59%. IPO:TBA

People Also Watch

US Crude Oil Spot

89.68 Price
+2.160% 1D Chg, %
Long position overnight fee 0.0426%
Short position overnight fee -0.0670%
Overnight fee time 21:00 (UTC)
Spread 0.03

Market analysis

Merrimack Pharmaceuticals, Inc. (MACK) Stock Moves 0.73%: What You Should Know

Merrimack Pharmaceuticals, Inc. (MACK) stock is up 0.73% in the last day. For details on what happened in the market, see our analysis.

07:00, 8 August 2022

Learn more about

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading